Pfizer is spending about $43 billion to reach deeper into new cancer treatments that target tumour cells while sparing surrounding healthy tissue. The pharmaceutical giant said Monday it will pay $229 in cash for each share of Seagen Inc. Pfizer then plans to let the biotech drug developer “continue innovating,” except with more resources than it would have alone, Pfizer Chairman and CEO Albert Bourla told analysts.